Resource 01 · Strategy & Commercialisation

Product Commercialisation Readiness Framework

What must be demonstrated before an idea becomes a commercially viable, manufacturable and market-ready product?

Educational framework
Edition
1.0
Last technical review
18 November 2026
Full methodology
10 min read

Developed and curated by Shamim Quresh · Editorial methodology

Level 1 · Understand · about two minutes

The framework at a glance

A launch date is a planning constraint, not proof of readiness. Most product failures are not caused by a lack of effort but by decisions taken in the wrong order: artwork before claims are settled, tooling before the formula is stable, campaign spend before supply is reliable. A stage-gate structure makes the remaining uncertainty visible and assigns it to named people.

Controlling question
Should this product exist, and is it ready to launch?
Key decision record
Stage-gate decision log
Role in the library
Coordinates the overall lifecycle
Applies to
Consumer products in general, with examples from cosmetics and beverages. It is a planning aid: completing it does not guarantee safety, legal compliance or commercial success.

The 9 stages

Stage 01 of 9 · ends in a gate decision

Opportunity assessment

Is there a meaningful problem, and nothing obviously fatal?

Essential deliverables

  • Opportunity thesis and assumption register
  • Feasibility memo and project charter
  • Product requirement specification
  • Prototype register and test reports
  • Master manufacturing instructions and supply plan
  • Market release checklist and regulatory evidence index
  • Launch dashboard and incident log
  • Stage-gate decision records

Common mistakes

  • Treating the launch date as evidence of readiness.
  • Leaving regulatory scoping until artwork.
  • Calling a gap 'conditional' when it is a safety or legal requirement.
  • Modelling price without discounts, channel fees and returns.
  • Buying tooling before the formula and pack are stable.

After reading, you should be able to

  • Describe the nine stages and the evidence each gate requires.
  • Distinguish Go, Conditional Go, Hold and Stop / Redesign, and explain why safety and legal requirements can never be conditional.
  • Calculate contribution per unit, break-even units and a reorder point, and test them against downside scenarios.
  • Plan overlapping workstreams without compressing safety work.

How it connects to the other frameworks

Level 2 · Study · the complete methodology

Work the method

Purpose and governing principle

Commercialisation is the disciplined conversion of a plausible opportunity into a product that can be lawfully sold, reliably supplied, economically sustained and credibly supported after launch. A launch date is a planning constraint, not proof of readiness. The correct question is not “Have all nine stages been ticked?” but “Is the residual uncertainty acceptable to the named decision-makers, on the basis of traceable evidence?”

Nine stages with explicit gates

StageCore tasksEssential inputsRequired outputsCritical dependency / exit criterion
1. Opportunity assessmentDefine problem, category, user, alternatives, price corridor, unmet need; scan regulation and IPMarket observation, interviews, competitor samples, channel economicsOpportunity thesis, market map, assumption register, kill criteriaEvidence of a meaningful problem; plausible addressable demand; no obvious fatal prohibition
2. Feasibility and business caseEstimate technical difficulty, bill of materials, factory fit, unit economics, cash-cycle and worst casesProduct concept, indicative suppliers, process options, regulatory scopingFeasibility memo, rough target cost, risk-ranked project charterA feasible path exists within capital, timing and risk tolerances
3. Product requirements and concept freezeTranslate needs into measurable performance, user, packaging, claim, sustainability and market requirementsConsumer insight, feasibility, channel briefProduct requirement specification (PRS), target product profile, claim hypothesis listRequirements have test methods, acceptance criteria and owners
4. Development and proof of conceptPrototype formula/product, screen ingredients, evaluate packaging, run early tests and sensory studiesPRS, approved raw materials, lab capabilityPrototype register, preliminary performance evidence, initial hazard assessmentAt least one viable technical concept; unresolved risks documented
5. Design verification and validationConfirm technical requirements, fit-for-use, stability, safety, compatibility, scale-up assumptions and claim supportPrototype candidate, test plan, methods, representative materialsVerified specification, test reports, safety dossier inputs, validation summariesFailures investigated; evidence sufficient for intended use and market
6. Industrialisation and supply readinessSelect manufacturer, qualify suppliers, map process, assess capacity, set controls, perform transfer trialsApproved product design, packaging, equipment, suppliersMaster manufacturing instructions, specification hierarchy, trial report, supply planFactory can demonstrate controlled manufacture at intended scale
7. Legal, quality and launch readinessComplete market-specific records, label review, product notification/registration where applicable, logistics and recall preparationStable technical design, safety documentation, product labels, company/operator detailsMarket release checklist, quality agreement, regulatory evidence index, approved artworkNamed authorised release decision; market-specific obligations met
8. Controlled launchPilot channels, monitor orders, complaints, returns, stock, repeat purchase and real-world product responseReleased stock, trained teams, contingency planLaunch dashboard, incident log, customer feedback, channel performanceControlled distribution, active escalation routes and capacity to respond
9. Post-launch optimisationTrack quality trends, demand, gross margin, experience, changes, adverse events and end-of-lifeField data, batch data, channel data, approved change proceduresProduct review, CAPA/change actions, portfolio decision, revised forecastContinue, improve, expand, pause or retire on evidence

Gate decisions are not binary checkboxes

A gate review records one of four dispositions: GO, CONDITIONAL GO (only for explicitly bounded non-critical gaps), HOLD (obtain more evidence) or STOP/REDESIGN. A missing safety assessment, unresolved critical defect, prohibited ingredient or required market authorisation cannot be waived as a mere commercial exception. Conditional go must name the missing evidence, accountable owner, deadline, exposure limit and automatic stop condition.

Workstream dependencies

Regulatory scoping begins in stage 1, not stage 7. Claims research begins before formulation locks. Packaging compatibility begins while formulas are still adaptable. Manufacturer capability is checked before the laboratory falls in love with an unmanufacturable viscosity. Commercial photography and campaign spend are delayed until the product's appearance, pack and claims are sufficiently stable. These overlaps compress lead time without compressing safety work.

Stage-gate scorecard

Use five 0–4 ratings: consumer desirability, technical feasibility, unit economics, manufacturing robustness, market compliance. A rating of 0 means no evidence; 1 = conjecture; 2 = preliminary evidence; 3 = verified against defined criteria; 4 = repeatably demonstrated in a representative setting. The score is a discussion instrument, not an approval algorithm: a severe regulatory or safety deficit overrides a high aggregate score.

Quantitative commercial tools

  • Contribution per unit = net realised selling price − variable product cost − variable fulfilment/channel cost − expected returns/allowances.
  • Break-even units = launch-period fixed costs ÷ contribution per unit, provided contribution is positive.
  • Reorder point = expected demand during replenishment lead time + safety stock. Estimate variability explicitly; do not copy arbitrary safety-stock percentages.
  • Cash conversion exposure = when inventory and deposits are paid versus when customer cash is collected, including channel payment terms and minimum order quantities.
  • Sensitivity triangle: recalculate the business case simultaneously for lower volume, higher cost and slower replenishment. Optimism compounds when assumptions are correlated.

Worked illustration — not a forecast. A product with net realised revenue of $18/unit and $10.50/unit in variable costs has $7.50 contribution. If attributable fixed launch costs total $15,000, break-even is 2,000 units before taxes and financing effects. If promotions lower realised revenue to $15 while costs rise to $11, contribution falls to $4 and break-even rises to 3,750 units. Pricing and supplier negotiations therefore belong in the same model.

Unconventional but disciplined problem-solving techniques

  1. Premortem laboratory. Convene formulation, brand, production, regulatory and logistics personnel. Imagine the launch failed in six months; each person writes the most likely cause. Convert the top causes into experiments and controls before committing to capital.
  2. Reverse the factory. Start with the customer's expected unboxing and use experience, then trace backward through fill volume, pump/tube behaviour, packaging line limits, formula rheology, ingredients and procurement. This uncovers requirements hidden by departmental silos.
  3. Constraint auction. Give each team a limited number of “constraint tokens” to allocate to cost, speed, sustainability, aesthetics, performance and risk. Explain why each constraint is expensive. This exposes conflicts before teams optimise different objectives.
  4. Evidence debt register. Treat every untested assumption like technical debt, with an owner and the cost of discovering it late. Prioritise high-impact, cheap-to-test uncertainties first.
  5. Smallest reversible experiment. Before buying production tooling, test one deliberately difficult failure mode using the smallest representative sample possible, then confirm representativeness before extrapolating.
  6. No-regrets parallelism. Run supplier discovery, early market interviews, claims scoping and packaging risk assessment simultaneously; sequence irreversible spend behind evidence gates.

Example deliverables and reusable template

Commercialisation decision record

FieldEntry
Product / market / revision[IDs]
Current stage / gate meeting[Stage; date; reviewers]
Decision / rationale[Go, conditional go, hold, stop; why]
Evidence reviewed[Links to controlled versions]
Open critical risks[ID; severity; owner; mitigation]
Financial sensitivity[base / downside / extreme case]
Conditions and stop triggers[metric; owner; due date]
Next stage deliverables[named accountable person]

Applying the framework

Opportunity assessment matrix

Score each criterion with the same 0–4 evidence scale used at the gates. The point is to expose where the evidence is thin, not to produce a single number.

CriterionEvidence that countsWarning sign
Problem significanceObserved behaviour, workarounds people already pay for, unprompted complaintsInterest expressed only when the idea is described to them
Addressable demandPurchase occasions you can count in a defined channel and geographyA national market-size figure with no route to the customer
AlternativesDirect, indirect and non-consumption options mapped with prices"No competitors"
Price corridorShelf and online prices of real alternatives; willingness-to-pay tested against a concrete offerA price set only by working backwards from a target margin
Channel fitNamed retailer or channel requirements, margins and payment termsAssuming a channel will list the product because it is good
Regulatory and IP scanProduct classification, restricted ingredients or claims and freedom-to-operate questions loggedClassification left until artwork
Fit with capabilitySkills, partners and capital that exist or can realistically be securedThe plan depends on capabilities nobody has yet

Technical feasibility matrix

QuestionWhat to examineTypical evidence at stages 2–4
Can it be made at all?Format, key materials, known formulation or engineering limitsLiterature, supplier technical data, bench prototypes
Can it be made to specification?Each requirement in the product requirement specification and how it will be testedDraft requirements-to-test matrix
Can it be made at scale?Equipment, batch size, fill format and the manufacturer's capabilityManufacturer conversation, equipment list, trial plan
Can it be made at the target cost?Bill of materials, yield assumptions, packaging and conversion costIndicative quotations, sensitivity ranges
Can it be sold in the intended markets?Classification, ingredient status, labelling and registration routesRequirements register entries with sources
Can it be supplied reliably?Lead times, minimum order quantities, single-source materialsSupplier list with lead times and alternatives

Risk register

Record each risk once and link it to the stage where it must be resolved.

FieldContent
Risk IDStable identifier, for example RSK-014
DescriptionCause → event → consequence, in one sentence
CategorySafety, regulatory, technical, supply, commercial, reputational
Severity / likelihood / detectabilityRated with a documented rationale; a severe safety or legal risk is never averaged away
OwnerOne named person
ResponseAvoid, reduce, transfer or accept, with the specific action
Evidence of controlThe record that shows the action worked
GateThe stage-gate by which it must be closed or formally accepted
Status and review dateOpen, controlled, closed, accepted

Commercial readiness checklist

Before a stage 7 release decision, confirm with evidence rather than assertion:

  • Product: specification approved; stability and compatibility conclusions recorded; open tests listed with their consequence.
  • Safety and regulatory: market-specific obligations identified, met and indexed; responsible parties named; labels approved for each market.
  • Supply: manufacturer and suppliers qualified; quality agreement signed; first production batches planned against forecast; reorder point calculated.
  • Commercial: price, discount structure and channel terms reflected in the contribution model; downside case reviewed.
  • Customer: product education, customer-service answers and complaint routes ready; returns process defined.
  • Recall readiness: lot-to-customer traceability tested; contacts and decision rights agreed.

Launch dependencies

Some decisions cannot be finalised until others are stable. The most common critical path:

This decision……depends onWhy
Final artworkFormula revision, claims wording, market list, net contentsEvery change to these alters the label
Claims wordingSubstantiation evidence and market classificationA claim can change the regulatory category
Packaging orderCompatibility and dispensing results in the final packA compatible bulk can fail in the pack
Production bookingTransfer trial results and supplier lead timesThe factory slot is wasted if materials are late
Campaign photographyFinal pack, product appearance and approved claimsReshoots are expensive and slow
Release decisionBatch record review, required market evidence, open deviations closed or assessedRelease is a quality decision, not a calendar date

Running a premortem

  1. Agree the scenario: "It is six months after launch and the product has failed."
  2. Each participant writes, silently and independently, the single most likely cause.
  3. Read the causes aloud without discussion; cluster them.
  4. For each cluster, ask: what early signal would we see, and what is the cheapest test or control we could run now?
  5. Add the results to the risk register and the evidence debt register with owners and dates.

Reverse-engineering from the customer experience

Write the first five minutes of the customer's experience in concrete detail: opening the parcel, the weight in the hand, the first dispense, the feel on skin, the smell, the residue, the second use. Then ask what must be true at each upstream step for that experience to happen — fill weight and headspace, closure torque, viscosity range, ingredient grade, supplier lead time. Each answer becomes a requirement with an owner.

Failure scenarios and troubleshooting

SymptomLikely underlying causeFirst response
Launch date fixed before requirements existCalendar treated as evidence of readinessRe-baseline the plan from the critical path; make the date a constraint to test
Contribution turns negative after launchPromotions, channel fees or returns missing from the modelRebuild the unit model with net realised price and all variable costs
Artwork reprinted repeatedlyClaims, formula or market list changing after artwork startedFreeze claims and formula revision before artwork; link artwork to revision IDs
Factory cannot reproduce the laboratory sampleScale-dependent process variables not transferredHold launch; run a witnessed transfer trial against the same critical quality attributes
Stock-out within weeksReorder point set without lead-time variabilityRecalculate with observed demand and lead-time variation; review minimum order quantities
Conditional go never closesConditions without owner, deadline or stop triggerConvert to hold until the condition is fully specified

For the shared master-data keys, the five-question executive review and the 90-day implementation sequence, see the shared toolkit on the library page.

Level 3 · Apply · educational tools

Practise the method

These tools are teaching simulations. They use illustrative data, show their assumptions and are not validated scientific, regulatory or financial instruments.

Conceptual demonstration

Commercialisation roadmap and gate review

Select any of the nine stages to see its purpose, inputs, deliverables, dependencies, decision-makers, risks, evidence and exit criteria. Then hold a gate review: mark which exit checks have evidence and take one of four decisions.

Stage 01 of 9

Opportunity assessment

Purpose
Establish whether there is a meaningful problem worth solving, for a reachable customer, with no obvious fatal barrier.
Key activities
Define problem, category, user, alternatives, price corridor and unmet need; scan regulation and intellectual property.
Required inputs
Market observation, interviews, competitor samples, channel economics.
Required deliverables
Opportunity thesis, market map, assumption register, kill criteria.
Dependencies
None upstream. Regulatory scoping starts here, not at stage 7.
Decision-makers
Founder or sponsor, with commercial and technical leads.
Risks
Confirmation bias; mistaking interest for demand; missing a prohibition.
Evidence required
Observed behaviour and workarounds; counted purchase occasions; a classification scan.
Exit criteria
Evidence of a meaningful problem; plausible addressable demand; no obvious fatal prohibition.
Common reasons for failure
Opportunity defined by the founder's enthusiasm; no kill criteria written down in advance.
Gate review: which exit checks have evidence?
Gate decision
Go needs evidence for every exit check.
Not available: a safety-critical or legally mandatory item is open, and those can never be waived as a commercial exception.
Show the decision record as text
Gate decision record (illustrative)
Stage 1: Opportunity assessment
Decision: Not yet taken
Evidence in hand: none
Outstanding: [critical] Product classification and any prohibited ingredients or claims scanned for each target market; Problem observed in real behaviour, not only in answers to a pitch; Alternatives, including doing nothing, mapped with prices; Kill criteria written before more money is spent

Limits of this tool. A teaching set of exit checks, not a complete checklist. The tool enforces one rule from the framework: a safety-critical or legally mandatory gap can never be passed as a conditional go. Nothing you enter is saved or sent.

Conceptual demonstration

Commercial feasibility calculator

Change price, discounts, costs, fees, launch costs, order quantity and lead time, and watch contribution, break-even, revenue and inventory exposure move across conservative, base and optimistic cases.

Default values are illustrative. They reproduce the framework's worked example: a $18 net realised price and $10.50 variable cost give $7.50 contribution and break-even at 2,000 units. Any currency works.

Price
Variable costs
Launch and supply
ResultConservativeBaseOptimistic
Net realised price$17.00$18.00$18.00
Variable cost per unit$11.55$10.50$10.18
Contribution per unit$5.45$7.50$7.82
Contribution margin32.1%41.7%43.4%
Break-even units2,7532,0001,920
Weeks to break even32.816.712.8
Revenue over 26 weeks$37,128$56,160$70,200
Result after fixed costs, 26 weeks−$3,097$8,400$15,479
Reorder point (units)1,1791,1001,340
of which safety stock171140140
Weeks of cover from initial order35.725.020.0
Cash tied up in initial order$24,750$22,500$21,825
Initial stock unsold after 26 weeks816 units ($6,732)NoneNone
Sensitivity: break-even units in the base case
Price ↓ / Variable cost →−10%As entered+10%
−10%2,2232,6323,226
As entered1,7552,0002,326
+10%1,4501,6131,819

Read across a row to see how cost negotiations move break-even; read down a column for pricing. The conservative scenario is the framework's sensitivity triangle: lower volume, higher cost and slower replenishment at the same time, because optimism compounds when assumptions are correlated.

Assumptions and calculation method
  • Net realised price = list price × (1 − discounts).
  • Contribution per unit = net realised price − production − packaging − fulfilment − channel fees − returns and allowances.
  • Channel fees and returns are applied as a percentage of net realised price; returned units are assumed unsaleable.
  • Break-even units = fixed launch costs ÷ contribution per unit, only when contribution is positive. Before tax and financing.
  • Reorder point = weekly demand × lead time + safety stock. Safety stock = 1.65 × weekly standard deviation × √(lead time in weeks): roughly a 95% chance of not running out in a lead time, assuming fairly steady, normally distributed demand and a fixed lead time.
  • Conservative case: 70% of the volume, variable costs +10%, discounts +5 points, lead time ×1.5. Optimistic case: 125% of the volume, variable costs −3%. These adjustments are illustrative.
  • Not modelled: payment terms and cash timing, minimum order quantities, shelf life, taxes and duties.

Limits of this tool. Uses the framework’s formulas with stated assumptions. It ignores tax, financing, payment terms and minimum order quantities, and it is not a forecast or financial advice.

Working templates

Download the templates

Each file includes instructions, field definitions and example entries. Example entries are marked ILLUSTRATIVE and describe fictional products. All ten templates are listed on the library page.

References and further reading

Sources

Primary sources for verification. Listing a source is not a claim that every requirement in it applies to every product. Recheck laws, standards and market dates before commercial use.

  1. Voluntary standard (guidance note)

    The process approach in ISO 9001:2015 (opens in a new tab)

    International Organization for Standardization. Scope: Quality management systems in general.

    Explains the process approach, risk-based thinking and the Plan-Do-Check-Act cycle. Check for a newer edition of ISO 9001 before relying on clause references.

  2. Pharmaceutical methodology

    ICH Quality Guidelines: Q8(R2) Pharmaceutical Development, Q9(R1) Quality Risk Management, Q10 Pharmaceutical Quality System (opens in a new tab)

    International Council for Harmonisation. Scope: Medicines. Useful as scientific and risk-management methodology; not a legal requirement for cosmetics.

    Q8, Q9 and Q10 are designed to work together to support science- and risk-based approaches to quality.

Links and summaries last checked 18 November 2026.

Editorial methodology

These frameworks were developed and curated by Shamim Quresh, drawing on her professional practice in product development, formulation, manufacturing, branding and compliance.

They rely on published standards, regulations and established scientific principles, cited where they are used. That research and those publications are the work of their own authors and publishers.

AI tools assisted with drafting, structuring and checking the text, the interactive tools and the templates. Content is reviewed by Shamim before publication, and regulatory references were checked against official sources on the review date shown.

Worked examples, scenarios, results and data are illustrative. They do not describe experiments, tests or studies that Shamim has carried out, and no regulatory assessment of any product has been made.

Want to apply a framework to your own product?

I use these methods in consultancy work on product development, commercialisation, manufacturing and compliance. Tell me what you are building and where it is stuck.